Central serous chorioretinopathy, or CSC, is the fourth most common retinal disease, leading to age-related macular degeneration and retinal atrophy. Understanding of CSC's pathogenesis and potential therapeutic targets is currently limited. Researchers have now utilized next-generation sequencing to investigate the exosomal microRNA in the aqueous humor of patients with CSC. Here, miR-184 was found to be significantly upregulated. Lab tests using human choroidal endothelial cells showed that miR-184 suppressed both cell proliferation and migration, highlighting its angiostatic capacity. Moreover, STC2 was identified as a potential post-transcriptional target gene for miR-184, pointing to an imperative role in disease progression. While this study offers promising results, a robust body of large-scale and prospective studies is necessary to validate these novel findings. Such research holds potential in aiding the understanding, management, and treatment planning of CSC by utilizing miR-184 as a predictive biomarker for patient responses to anti-VEGF treatment.